Alkermes plc
NASDAQ:ALKS 4:00:00 PM EDT
| Market Cap (Intraday) | 3.97B |
| Current PE | 7.65 |
| Forward PE | 8.9 |
| 2yr Forward PE | 9.28 |
| 10-Day MA | $24.61 |
| 50-Day MA | $27.73 |
| 200-Day MA | $27.68 |
Alkermes plc Stock, NASDAQ:ALKS
Connaught House, 1 Burlington Road, Dublin, Dublin 4
Ireland
Phone: +353.1.772.8000
Number of Employees: 2100
Description
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.